Saturday, July 11, 2026

Drug profile · INN

dose-escalation

dose-escalation is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 5
Pipeline programs 33
News articles 0
Drug details — dose-escalation
Class
Route
Patents
5
Programs
33
Data quality
0.70

Quick answer

dose-escalation is an FDA-listed pharmaceutical active ingredient.

Key facts

INN dose-escalation

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. 223050 Phase 2 · GSK Glaxo Smith · Neoplasms, Prostate
  2. ARI-HER2 Phase 2 · George Institute for · Patients with HER2Positive Advanced Breast Cancer
  3. BB-301: Dose escalation phase 1b cohort 1 Phase 2 · Benitec Biopharma · Oculopharyngeal Muscular Dystrophy
  4. CLIN-01194-450 Phase 2 · Ipsen · Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Sq
  5. CM-24 and Nivolumab - Dose Escalation Phase 2 · PURPLE BIOTECH · Solid Tumor
  6. CRN09682-191 Phase 2 · Anaxis Pharma · Metastatic or locally advanced SST2-positive neuroendocrine
  7. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab Phase 2 · Nektar Therapeutics UK · Melanoma
  8. LB101-101 Phase 2 · Centessa Pharmaceuticals · Advanced solid tumors

Related patents

  1. US 12421310

    CD47 binding agents

    Expires 2045-09-18T00:00:00.000Z

    granted
  2. US 10335460

    IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions

    Expires 2039-06-27T00:00:00.000Z

    granted
  3. US 8865230

    Compositions and methods for treating parasitic infections

    Expires 2034-10-16T00:00:00.000Z

    granted
  4. US 8129510

    Minigene expression cassette

    Expires 2032-03-01T00:00:00.000Z

    granted
  5. US 7148193

    Compounds that bind to growth hormone receptor

    Expires 2026-12-07T00:00:00.000Z

    granted

Frequently asked questions

What is dose-escalation?

dose-escalation is an FDA-listed pharmaceutical active ingredient.